Articles tagged with: Stem Cell Transplant
Results from a recent retrospective study conducted in Germany suggest that treatment with novel agents followed by an autologous stem cell transplant may be an effective and safe salvage therapy for relapsed multiple myeloma patients who previously received a transplant.
The study investigators believe that this course of treatment could potentially “serve as a bridge” to a late donor transplant in certain patients.
However, the researchers point out that many of the patients included in the analysis did not receive novel agents as initial treatment. It is therefore unclear if …
BMI, Not Physical Activity, Associated With Risk Of Myeloma – Results of a large U.S.-based study sponsored by the AARP found that across all age groups, people with higher body mass index (BMI) were more likely to develop multiple myeloma. However, physical activity level at any age did not impact the likelihood of developing myeloma. Previous studies have investigated whether obesity increases a person’s risk of developing myeloma, but the results have been inconsistent. For more information, see the study in American Journal of Epidemiology (abstract).
Study On Timing Of Stem Cell Transplantation Shows Early Transplant Improves Progression-Free Survival – Results from a small, retrospective study conducted in China show that newly diagnosed myeloma patients who received Velcade (bortezomib)-based initial therapy and a stem cell transplant had significantly longer progression-free survival (42 months) compared to previously-treated patients who received the same combination of treatments at relapse (27 months). Although there was not a statistically significant difference in overall survival between the two groups of patients, there was a trend favoring early transplantation: five years from diagnosis, about 80 percent of the early-transplant patients were still alive, versus about 50 percent of the delayed-transplant patients. The trend to better survival in the early-transplant group, however, may be due to the fact that all patients in this group received a novel therapy (Velcade) as part of their initial therapy immediately after diagnosis. This was not the case for the late-transplant patients, some of whom received older treatment regimens as their initial treatment immediately after diagnosis. In both groups of patients, stem cell transplantation deepened the response to treatment. The transplant process increased the combined rate of near-complete and complete responses from 70 percent to 85 percent in the early-transplant patients, and from 56 percent to 81 percent in the late-transplant patients. For more information, see the study in the Chinese Journal of Cancer Research.
Study Sheds Light On Efficacy And Safety Of Preparative Therapy For Donor Stem Cell Transplantation – An Italian study of 196 myeloma patients who underwent donor (allogeneic) stem cell transplantation compared the outcomes of those who received myeloablative preparative therapy (high-intensity treatment that causes irreversibly low blood cell counts and requires stem cell transplantation) versus reduced-intensity preparative therapy (causes low blood cell counts and should be accompanied by stem cell transplantation) versus non-myeloablative preparative therapy (causes minimal reductions in blood cell counts and does not need to be accompanied by stem cell transplantation). All transplants were done using stem cells donated by unrelated donors. Patients had received a median of three lines of therapy prior to their donor transplant, and 89 percent of the patients had previously undergone at least one autologous (own) stem cell transplant. The results of the study show that patients who received non-myeloablative or myeloablative therapy had longer event-free and overall survival than those who received reduced-intensity therapy. Event-free survival was 10 months for those who received myeloablative therapy, 6 months for reduced-intensity therapy, and 13 months for non-myeloablative therapy. Overall survival was 29 months, 11 months, and 32 months, respectively. However, patients who received myeloablative therapy were most likely to experience fatal transplant-related complications. The one-year treatment related mortality rates were 29 percent for myeloablative therapy, 20 percent for reduced-intensity therapy, and 25 percent for non-myeloablative therapy. At three years, the rates were 37 percent, 31 percent, and 30 percent, respectively. The study investigators conclude that long-term disease control is still challenging and that more studies are needed to define the role of donor transplantation for myeloma using stem cells from unrelated donors. For more information, see the study in Biology of Blood and Marrow Transplantation (abstract).
The results of a small, retrospective study indicate that donor stem cell transplantation may be effective and well tolerated in multiple myeloma patients who have a deep response to initial therapy.
Specifically, the researchers found that for the majority of patients, stem cell transplantation deepened their initial response to a complete or stringent complete response.
Two years following transplantation, three-quarters of the patients were disease-free, which according to the researchers shows that donor transplantation may be a good tool for the prevention of early relapse and progression of the disease. …
Findings from a retrospective study show that there have been significant changes in the treatment of newly diagnosed multiple myeloma patients in the United States since 1999.
In particular, more patients are being treated soon after diagnosis. In recent years, the use of novel agents, such as thalidomide (Thalomid), Velcade (bortezomib), and Revlimid (lenalidomide), and stem cell transplantation have become more common. At the same time, the use of conventional chemotherapy, such as melphalan (Alkeran), vincristine (Oncovin), and doxorubicin (Adriamycin), as initial therapy has …
Stem Cell Remobilization With Mozobil Is Possible – Results of a small retrospective study conducted at City of Hope National Medical Center show that remobilization of stem cells with Mozobil (plerixafor) is possible in multiple myeloma patients. Specifically, the researchers found that most multiple myeloma patients (83 percent) who previously failed to collect enough stem cells with Mozobil to proceed to transplantation collected enough stem cells after a second round of mobilization with Mozobil. For more information, please refer to the study in the journal Transfusion (abstract).
Another Study Finds Link Between Cereblon Levels And Revlimid Efficacy – Results of a retrospective analysis conducted in Austria and Italy show that levels of the protein cereblon in patients’ myeloma cells may impact the efficacy of Revlimid (lenalidomide). The researchers found that newly diagnosed multiple myeloma patients with high cereblon levels responded better to treatment with Revlimid and dexamethasone (Decadron) than those with low cereblon levels. The results of the current study support results of previous studies that showed that cereblon is necessary for the immunomodulatory drugs – particularly Revlimid and Pomalyst (pomalidomide) – to be effective against multiple myeloma (see related Beacon news). For more information, please see the study in the British Journal Of Haematology (abstract).
Stem Cell Transplantation May Be More Effective In Amyloidosis Than Multiple Myeloma – Results of a recent retrospective analysis conducted at the Mayo Clinic indicate that patients with immunoglobulin light-chain amyloidosis may benefit more from stem cell transplantation than patients with multiple myeloma. Specifically, the researchers found that more light chain amyloidosis patients achieved a complete response, compared to multiple myeloma patients (40 percent versus 29 percent, respectively). Overall survival was also superior in patients with amyloidosis (9.4 years versus 5 years, respectively). The researchers found that even among those who achieved a complete response, survival was longer for those with amyloidosis. They therefore hypothesize that the biology of the two diseases is very different, despite the similarity in the two types of plasma cell disorders. For more information, please see the study in the journal Bone Marrow Transplantation (abstract).